[Application of pancreaticojejunostomy with pancreatic duct binding external drainage in laparoscopic pancreatoduodenectomy].

Objective: To examine the effect of pancreaticojejunostomy with pancreatic duct binding external drainage in laparoscopic pancreatoduodenectomy. Methods: The data of 21 patients who underwent laparoscopic pancreaticoduodenectomy in the same treatment group from January 2017 to October 2019 in Department of Hepatobiliary Surgery of the Second Hospital of Hebei Medical University were analyzed retrospectively.All patients underwent pancreaticojejunostomy with external drainage of pancreatic ducts.There were 12 males and 9 females, aged (63.1±8.1)years old (range: 46 to 77 years old), body mass index (24.8±3.2)kg/m(2)(range: 18.8 to 29.1 kg/m(2)).There were 3 cases of hypertension, 5 cases of diabetes, 3 cases of hypertension and diabetes, 3 cases of liver cirrhosis. Results: Laparoscopic pancreatoduodenectomy was successfully performed in all 21 patients.The operation time was (359.3±71.0)minutes, the pancreaticojejunostomy time was (23.8±7.4)minutes, the diameter of pancreatic duct was(3.3±0.6)mm, the intraoperative blood loss was (247.6±90.1)ml, the postoperative hospital stay was(13.7±4.9)days, the leakage of B-level fistula occurred in 1 case(4.8%), and there was no C-level pancreatic fistula.There were 3 cases of bile leakage, 1 case of incision infection, 2 cases of gastroparesis, 1 case of hydrops abdominis, no death and secondary operation. Conclusion: It is a simple and easy method of pancreatoenterostomy with pancreatic duct binding external drainage, which can reduce the incidence of pancreatic fistula and related complications after laparoscopic pancreatoduodenectomy for patients with high risk pancreatic fistula.

Comparison of the efficacy of febuxostat vs. benzbromarone in the treatment of gout: a meta-analysis in Chinese gout patients.

OBJECTIVE: Febuxostat and benzbromarone are two common drugs for the treatment of gout, but the clinical efficacy of these two drugs is controversial. This meta-analysis aimed to compare the efficacy of febuxostat and benzbromarone in the treatment of gout. MATERIALS AND METHODS: PubMed, Embase, and the Cochrane Library were searched for articles related to febuxostat and benzbromarone in the treatment of gout from inception to January 7, 2023. Titles and abstracts were reviewed in accordance with predesigned inclusion and exclusion criteria, and data were extracted independently. The Newcastle-Ottawa Scale (NOS) was used to evaluate the quality of the studies, and the continuous variables were expressed as the standard mean square error (SMD) by STATA 16 (Stata Corp., College Station, TX, USA). The sensitivity analysis was conducted by randomly removing a study, and the heterogeneity was analyzed by funnel plots and Egger's test. RESULTS: According to the search strategy, a total of 1,043 publications were retrieved from the three aforementioned databases, of which 45 publications were excluded due to duplication. Fourteen studies remained after screening titles and abstracts, and a total of 7 studies met the inclusion criteria after a comprehensive evaluation of the 14 studies. Meta-analysis showed that the uric acid (UA)-reducing effect of febuxostat is better than that of benzbromarone, while febuxostat showed a better ability to improve the estimated glomerular filtration rate (eGFR) and reduce Cr and blood urea nitrogen (BUN). In terms of hepatotoxicity, benzbromarone was not as potent as febuxostat in increasing alanine transaminase (ALT) and aspartate transaminase (AST), suggesting that benzbromarone has less hepatotoxicity. Moreover, there was no significant difference in the effect on blood lipid levels between the two drugs. CONCLUSIONS: The beneficial effect of febuxostat on renal function-related indexes such as the eGFR, Cr and BUN is significant, while benzbromarone is more effective in reducing UA and has relatively less hepatotoxicity. The specific efficacy of the two drugs needs to be confirmed by further research.

MiR-497 inhibits cell proliferation and invasion ability by targeting HMGA2 in pancreatic ductal adenocarcinoma.

OBJECTIVE: MicroRNAs have been implicated to play a crucial regulating role in human cancers. The study aims to explore the role and clinical significance of miR-497 in pancreatic ductal adenocarcinoma (PDAC). PATIENTS AND METHODS: The relative expression of miR-497 in human PDAC tissue samples and adjacent normal tissues was measured using the quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). Cell Counting Kit (CCK-8) assay, cell migration, and invasion assays were performed to detect cell proliferation and invasion ability. Downstream target gene was confirmed by using luciferase activity assays. QRT-PCR and Western blotting assays also were performed. RESULTS: We found that miR-497 expression was significantly downregulated in PDAC tissues and cells. Lower miR-497 expression associated with lymph node metastasis and predicts a poor prognosis in PDAC patients. In in vitro assay, we demonstrated that miR-497 overexpression inhibited cell proliferation, migration, and invasion of PDAC. Furthermore, we demonstrated that HMGA2 was a direct target of miR-497 in PDAC cells. MiR-497 inhibited cell proliferation and invasion by regulating HMGA2 expression. CONCLUSIONS: Our results indicated that miR-497 may serve as a predictor for PDAC and could be a novel target of PDAC treatment.

[Application of ARIMA model in predicting the incidence of tuberculosis in China from 2018 to 2019].

Objective: Autoregressive integrated moving average (ARIMA) model was used to predict the incidence of tuberculosis in China from 2018 to 2019, providing references for the prevention and control of pulmonary tuberculosis. Methods: The monthly incidence data of tuberculosis in China were collected from January 2005 to December 2017. R 3.4.4 software was used to establish the ARIMA model, based on the monthly incidence data of tuberculosis from January 2005 to June 2017. Both predicted and actual data from July to December 2017 were compared to verify the effectiveness of this model, and the number of tuberculosis cases in 2018-2019 also predicted. Results: From 2005 to 2017, a total of 13 022 675 cases of tuberculosis were reported, the number of pulmonary tuberculosis patients in 2017 was 33.68% lower than that in 2005, and the seasonal character was obvious, with the incidence in winter and spring was higher than that in other seasons. According to the incidence data from 2005 to 2017, we established the model of ARIMA (0,1,2)(0,1,0)(12). The relative error between the predicted and actual values of July to December 2017 fitted by the model ranged from 1.67% to 6.80%, and the predicted number of patients in 2018 and 2019 were 789 509 and 760 165 respectively. Conclusion: The ARIMA (0, 1, 2)(0, 1, 0)(12) model well predicted the incidence of tuberculosis, thus can be used for short-term prediction and dynamic analysis of tuberculosis in China, with good application value.

Overexpression of the PDCD2-like gene results in inhibited TNF-alpha production in activated Daudi cells.

Both PDCD2 and PDCD2-like proteins have PDCD2_C terminal domains, but their functions are still unclear. After analysis of their expression in Gene Expression Omnibus, we hypothesized that they played a role in inflammation. In Daudi cells exposed to lipopolysaccharides, PDCD2-like RNA was upregulated, whereas PDCD2 was downregulated. Overexpression of PDCD2-like gene effectively attenuated tumor necrosis factor (TNF)-alpha release but elevated interleukin (IL)-6 and PDCD2 expression induced by lipopolysaccharide (LPS). It is possible that both proteins have anti-inflammatory effects like IL-6. The results have implications for understanding the function of PDCD2/PDCD2-like proteins and may help in the development of novel anti-inflammatory drugs.

MiR-519d inhibits prostate cancer cell proliferation, cycle and invasion via targeting NRBP1.

OBJECTIVE: To investigate the effects of miR-519d on the proliferation, cycle and invasion of human prostate cancer PC3 cells and its possible molecular mechanism. MATERIALS AND METHODS: The proliferation, cycle, and invasion of human prostate cancer PC3 cells were detected via cell counting kit-8 (CCK-8) and transwell assay. The expression of NRBP1 mRNA was detected via reverse transcription-polymerase chain reaction (RT-PCR). Western blotting was used to detect the expression of NRBP1, cyclin D1, and epithelial-mesenchymal transition (EMT) markers. RESULTS: The expression of miR-519d in prostate cancer was decreased, which was correlated with tumor size, metastasis, and staging. Proliferation, cycle, and invasion of PC3 cells were significantly decreased after overexpression of miR-519d. Bioinformatics analysis and Western blotting showed that there was a potential miR-519d binding site in NRBP1 3'-UTR, and overexpression of miR-519d significantly inhibited the expression of NRBP1. The expression of E-cadherin in PC3 cells overexpressing miR-519d was up-regulated, and the expressions of N-cadherin, cyclin D1, vimentin, fibronectin, and Snail were down-regulated. CONCLUSIONS: MiR-519d can repress the proliferation, cycle, and invasion of prostate cancer PC3 cells by inhibiting NRBP1.

Use of asymmetric somatic hybridization for transfer of the bacterial blight resistance trait from Oryza meyeriana L. to O. sativa L. ssp. japonica.

Bacterial blight is one of the major diseases affecting rice productivity. To improve the resistance of cultivated rice to bacterial blight, we introduced a bacterial blight resistance trait from Oryza meyeriana, a wild rice species, into an elite japonica rice cultivar (Dalixiang) using asymmetric somatic hybridization. One hundred and thirty-two independent lines were regenerated. The hybrid plants possessed several morphological features of the donor species, O. meyeriana. Random amplified polymorphic DNA analysis revealed that hybrid plants exhibited banding patterns derived from their parental genotypes. For the majority of the hybrids, resistance to bacterial blight pathogens was intermediate to that observed for O. meyeriana and O. sativa (cv. Dalixiang). Four of the hybrid lines exhibited a high bacterial blight resistance, but it was less than that observed for O. meyeriana. These results demonstrate that O. meyeriana can be used as a good genetic source for improving bacterial blight resistance in commercial rice cultivars through asymmetric somatic hybridization.